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Abstract 
Background: The intestinal barrier plays an important role in the defense against infections, and nutritional, endo‑
crine, and immune functions. The gut microbiota playing an important role in development of the gastrointestinal 
tract can impact intestinal permeability and immunity during early life, but data concerning this problem are scarce.
Methods: We analyzed the microbiota in fecal samples (101 samples in total) collected longitudinally over 
24 months from 21 newborns to investigate whether the markers of small intestinal paracellular permeability (zonu‑
lin) and immune system development (calprotectin) are linked to the gut microbiota. The results were validated using 
data from an independent cohort that included the calprotectin and gut microbiota in children during the first year of 
life.
Results: Zonulin levels tended to increase for up to 6 months after childbirth and stabilize thereafter remaining at a 
high level while calprotectin concentration was high after childbirth and began to decline from 6 months of life. The 
gut microbiota composition and the related metabolic potentials changed during the first 2 years of life and were 
correlated with zonulin and calprotectin levels. Faecal calprotectin correlated inversely with alpha diversity (Shan‑
non index, r = − 0.30, FDR P (Q) = 0.039). It also correlated with seven taxa; i.a. negatively with Ruminococcaceae 
(r = − 0.34, Q = 0.046), and Clostridiales (r = − 0.34, Q = 0.048) and positively with Staphylococcus (r = 0.38, Q = 0.023) 
and Staphylococcaceae (r = 0.35, Q = 0.04), whereas zonulin correlated with 19 taxa; i.a. with Bacillales (r = − 0.52, 
Q = 0.0004), Clostridiales (r = 0.48, Q = 0.001) and the Ruminococcus (torques group) (r = 0.40, Q = 0.026). When time 
intervals were considered only changes in abundance of the Ruminococcus (torques group) were associated with 
changes in calprotectin (β = 2.94, SE = 0.8, Q = 0.015). The dynamics of stool calprotectin was negatively associated 
with changes in two MetaCyc pathways: pyruvate fermentation to butanoate (β = − 4.54, SE = 1.08, Q = 0.028) and 
Clostridium acetobutylicum fermentation (β = − 4.48, SE = 1.16, Q = 0.026).
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Background
The intestinal barrier plays important role in the defense 
against infections, apart from its essential nutritional, 
endocrine, and immune functions [1]. Multiple factors 
impact intestinal permeability in infants, including ges-
tational age, mode of delivery and feeding, and various 
diseases [2]. Increased gut barrier permeability allows the 
optimal nutrient uptake and leads to increased immune 
tolerance [3]; on the other hand, increased permeability 
to foreign antigens, including intestinal bacteria, might 
result in inflammation and systemic hypersensitivity [3, 
4]. The gut barrier of a newborn is highly permeable; 
importantly, the permeability decreases during a process 
known as “gut closure” [5]. The exact time of this pro-
cess in humans, regulated by growth factors, hormones 
and breast milk is unknown but has been proposed to 
take place around 22nd week of life [6]. It could also be 
hypothesized that gut microbiota may be involved in this 
process [6, 7]. Of note, gut permeability can be assessed 
via the analysis of the absorption of various substances 
[8], as well as via the measurement of blood and stool 
markers, including zonulin and calprotectin [9].
Zonulin (ZON), an analog of the cholera comma toxin 
(ZOT, zonula occludens toxin) [10, 11] shown to regulate 
paracellular transport within the small bowel [12–14]. 
This protein is synthesized in the liver and epithelial 
cells of the intestine and is a component of multi-pro-
tein membrane complexes (claudin-occludin-guanylate 
kinase-like proteins zonula occludens (ZO)-1, ZO-2, and 
ZO-3) forming tight junctions (TJ) [15]. In fact, zonu-
lin regulates the tightness of TJ, which is an important 
part of the proper function of the intestinal barrier [16]. 
Increased zonulin concentrations correlate positively 
with small intestinal permeability [17], a phenomenon 
discovered in the context of inflammatory and autoim-
mune disease [18–21], and could be considered as a bio-
marker for systemic inflammation [22].
Human calprotectin is a 24  kDa dimer formed by the 
protein monomers S100A8 (10,835  Da) and S100A9 
(13,242 Da), and makes up to 60% of the soluble proteins 
in the cytosol of human neutrophils [23, 24]. The sources 
of calprotectin in newborns are breast milk and resident 
and non-resident myeloid cells [25]. In fact, fecal calpro-
tectin is used in older children and adults as a marker 
for inflammatory bowel diseases  (IBD); there is a body 
of evidence correlating calprotectin with  IBD, cow-milk 
allergy, atopic disease and other gastrointestinal disor-
ders [26]. Of note, calprotectin has the potential to be 
used as an indirect marker of gut permeability [27]. How-
ever, its role as a marker of inflammation was not con-
firmed in neonates [25].
In our previous study [28] we found that some mater-
nal–fetal factors are associated with increased concentra-
tion of fecal calprotectin and zonulin in children during 
the first 2 years of life. Additionally, we found that after 
birth, zonulin levels increased up until 12  months of 
age, remaining high thereafter, while calprotectin levels 
decreased until six months of age, stabilizing thereafter 
[29]. Of note, in this previous study, we did not assess the 
fecal microbiota, which was a significant limitation; we 
were not able to trace the relationships between the fecal 
microbiome and the concentrations of the abovemen-
tioned stool markers. Therefore, in this study, we decided 
to analyze the microbiota in faecal samples collected lon-
gitudinally over 24  months from 21 subjects to test the 
hypothesis that small intestinal barrier permeability is 
linked to the gut microbiota. Moreover, we validated the 
observed results via comparison with the data obtained in 
the study by Willers et  al. (Hannover Medical School—
HMS cohort) who measured the relationship between 
calprotectin and gut microbiota in children during the 
first year of life [25].
Methods
Subjects
The present observational prospective cohort study con-
tinues research efforts in the context of intestinal bar-
rier function in a cohort of Polish newborns, described 
in detail in previous publications [28, 29]. Twenty four 
healthy full-term newborns at the Department of Obstet-
rics, Gynecology and Neonatology, the Pomeranian 
Medical University/Independent Public Clinical Hospital 
No. 2 in Szczecin (PMU cohort) were initially recruited 
to this study. Longitudinal sampling was performed for 
over 24  months. Three newborns were excluded due to 
an inadequate number of samples. In total, 21 newborns 
(101 samples in total) were included in the study, with at 
least four longitudinal stool samples available (the sample 
Conclusions: The small intestinal paracellular permeability, immune system‑related markers and gut microbiota 
change dynamically during the first 2 years of life. The Ruminococcus (torques group) seems to be especially involved 
in controlling paracellular permeability. Staphylococcus, Staphylococcaceae, Ruminococcaceae, and Clostridiales, may 
be potential biomarkers of the immune system. Despite observed correlations their clear causation and health conse‑
quences were not proven. Mechanistic studies are required.
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availability matrix is provided in Additional file 1: Figure 
S1). Samples were taken at the following points in time—
meconium (P1, n = 8), 7 days (P2, n = 20), 1 month (P3, 
n = 19), 6  months (P4, n = 20), 12  months (P5, n = 21) 
and 24 months (P6, n = 13) (Additional file 1: Figure S2) 
after birth. The study was conducted using the results 
obtained for the time points P2-P6. The measured mark-
ers and the meconium microbiota composition (P1) 
reflect the perinatal period. Therefore the values obtained 
at this time point were used instead to validate the micro-
biota analysis (the meconium microbiota is expected to 
be clearly distinguishable from the microbiota obtained 
at other time points). The participants’ characteristics are 
shown in Table 1.
All included newborns were exclusively breastfed dur-
ing the first week of life. The children were healthy and 
did not take antibiotics at the time the samples were 
collected. For validation, we used independent Illumina 
MiSeq 16S rRNA data of the same hypervariable region 
(V3–V4) derived from 227 stool samples of healthy term 
children enrolled in the HMS cohort. They were tested at 
seven time points (1, 2, 10, 30, 90, 180 and 360  days of 
age). For the sake of compatibility with the PMU cohort, 
five time points were selected: 1 day (P1, n = 43), 10 days 
(P2, n = 42), 30  days (P3, n = 47), 180  days (P4, n = 43) 
and 360 days (P5, n = 52) of age.
Determination of the fecal zonulin and calprotectin 
content
The concentrations of zonulin and calprotectin in the 
fecal samples were measured as previously described [28, 
29].
Sample collection, DNA extraction and sequencing
Stool samples were collected from diapers using a stand-
ardized biological material collection kit (Stool Sample 
Application System (SAS); Immundiagnostik, Bensheim, 
Germany). The samples were collected by previously 
trained hospital staff or by the parents according to an 
established procedure and stored in a refrigerator (for 
a maximum of eight hours) before transport. Transport 
to the laboratory took no longer than 60 min, at 6–8 °C. 
The stool samples were then frozen at − 20  °C until 
metagenomic analyses were conducted. Microbiome 
DNA extraction was performed using the Genomic Mini 
AX Bacteria + Spin and Genomic Mini AX Soil Spin 
kits (A&A Biotechnology, Gdynia, Poland) following 
the manufacturer’s protocol. DNA concentrations were 
determined by fluorometry (DeNovix DS-11 FX + Spec-
trophotometer/Fluorometer, Wilmington, DE, USA). 
Samples were subsequently stored at − 20  °C. Metagen-
omic libraries of the V3–V4 hypervariable region of the 
16S rRNA gene were constructed and further sequenced 
on the MiSeq platform (paired-end 2 × 250 bp) using V2 
chemistry from Illumina (Illumina, San Diego, CA, USA). 
Next generation sequencing (NGS) was performed by 
Genomed S.A., Warsaw, Poland.
For validation, we used the independent Illumina 
MiSeq 16S rRNA data of the same hypervariable region 
(V3–V4) derived from the 227 stool samples of healthy 
term children enrolled in the HMS cohort.
16S sequencing sample processing
The sequences were processed using LotuS 1.62 [30]. 
LotuS clusters operational taxonomic units and gen-
erates taxonomic-level abundances tables. UPARSE 
de novo sequence clustering removed chimeric OTUs 
with 1470 OTUs (PMU cohort) and 923 OTUs (HMS 
cohort) remaining. OTU seed sequences were classified 
by BLAST lower ancestor comparison to SILVA (1.32). 
The Rarefaction Toolkit (RTK) was used to normalize 
the abundances on all taxonomic levels [31]. Two sam-
ples were removed due to their low number of bacterial 
reads from the PMU cohort (read counts of 246 and 134), 
resulting in a final rarefaction depth of 1117 16S reads, 
yielding a count of 594 genera resolved at this sequenc-
ing depth and the final sample size of 101 was obtained. 
Moreover, 108 samples were removed due to their low 
number of bacterial reads from the HMS cohort (read 
count less than 1000), resulting in a rarefaction depth of 
1000 16S reads, yielding 484 genera and the final sample 
size of 227.
Table 1 Characteristics of study participants
C, Cesarean section, V, vaginal delivery, N, natural, F, formula; P1, meconium, P2, 7th day, P3, 1st month, P4, 6th month, P5, 12th month, P6, 24th month
Characteristic P1 (n = 8) P2 (n = 20) P3 (n = 19) P4 (n = 20) P5 (n = 21) P6 (n = 13)
Sex (F/M) 4/4 9/11 10/9 9/11 10/11 8/5
Mode of delivery (C/V) 5/3 11/9 11/8 12/8 12/9 6/7
Birth weight (g) 3472 ± 507 3320 ± 548 3311 ± 518 3322 ± 550 3341 ± 543 3352 ± 582
Body weight (kg) – 3.36 ± 0.54 4.49 ± 0.74 8.26 ± 1.18 10.40 ± 1.29 13.00 ± 1.68
Feeding method (N/F) 8/0 20/0 15/4 9/11 4/17 0/13
Breastfeeding time (weeks) 36.2 ± 25.6 30.0 ± 26.7 27.1 ± 24.9 27.9 ± 26.9 28.9 ± 26.6 27.1 ± 26.3
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The alpha diversity (Shannon, Simpson, Chao1, Even-
ness) was computed using RTK taking the genus median 
alpha diversity over ten rarefaction cycles. The beta 
diversity was calculated on a rarefied genus-level abun-
dance table using the Bray–Curtis dissimilarity metrics 
and visualized as principal coordinate analysis (PCoA). 
Taxa that were present in less than 20% (PMU cohort) 
and 10% (HMS cohort; a lower taxa prevalence was used 
to allow the comparison) of samples were removed.
To predict the metabolic profile of gut microbiota, we 
used the PICRUSt2 tool [32]. The prediction of MetaCyc 
metabolic pathways was conducted on the non-rarefied 
OTU abundance table from which rare OTUs (present 
in less than 20% of samples with a minimum count of 3) 
were removed. In order to address the issue of compo-
sitional data, the taxa and predicted MetaCyc pathway 
abundances (not rarefied but filtered to match the rare-
fied data) were transformed by generating 128 Monte 
Carlo instances of the Dirichlet distribution for each gut 
sample, followed by center-log transformation of each 
instance [33]. Analyses were performed for each instance 
separately and the results were then averaged over 128 
instances.
Power calculation
With N = 21 time series, it is true our statistical power 
may be limited. While this would not decrease confi-
dence in findings where we conclude significance (type 
I errors) it may place us at risk for missing associations, 
and challenges any interpretation of negative findings. As 
both permeability markers and microbiome features shift 
over time as the gut matures and diet shifts, their asso-
ciation may be driven by shared dependency on this third 
factor. First, we consider, as the closest representative 
test for which power calculations are straightforward, the 
analysis of coupled changes in e.g. a permeability marker 
versus microbial taxa through (Pearson) correlation 
with N = 21 samples each paired across two time points, 
resulting in N = 21 time point differences. We consider 
multiple testing considerations here to be reflected as 
per Bonferroni correction for Nt = 50 gut genera, mak-
ing for an adjusted alpha = 0.1/50 = 0.002. Under con-
vention of considering r = 0.5 as a "large" correlation, we 
achieve (running as "pwr.r.test (alternative = "two.sided", 
n = 21, sig.level = 0.002, r = 0.5)") a statistical power of 
only ~ 21%, meaning it is likely that we are overly con-
servative due to limited sample size, and that there may 
be several more of these associations at least this strong 
which remains to be shown robust in a larger study. 
However, this does not detract from our confidence in 
the associations where we do conclude significance, as it 
rather is more likely we miss associations between per-
meability and microbiota. This has no real bearing on 
whether the associations are direct or indirect via time 
progressing both as a third factor, however. Here, sup-
port of a direct link would come from the association 
achieving significance not only for the correlation of dif-
ferences within time courses between time points, but 
between donors within time points. This corresponding 
power calculation here is essentially the same (Nt = 21, 
alpha = 0.002, two-sided, taking r = 0.5 as a "large" corre-
lation) meaning our power is also ~ 21% at concluding an 
effect of similar size is a direct association. However, as 
we are similarly underpowered to conclude significance 
there, we expect to underestimate rather than overes-
timate inference of direct versus indirect relationships. 
All in all thereforewe cannot be fully certain either way 
whether concluded associations are direct or indirect, 
which concern must be kept in mind in comparison of 
our findings to previous literature.
Statistical analysis
All statistical analysis was performed using R (version 
4.0.0, R Foundation for Statistical Computing, Vienna, 
Austria). Changes over time in the context of perme-
ability biomarkers (zonulin and calprotectin), the gut 
alpha diversity indices, gut composition principal coor-
dinate scores, or gut taxa and pathway abundances 
were analyzed using mixed-effects models. Time points 
(P) were treated as the fixed effect and the newborn IDs 
as the random effect, accounting for repeated sampling 
of the same individual. The significance of the time 
point variable was tested via comparison of the likeli-
hoods of the two nested models (likelihood ratio test, 
LRT): without (null model) and with (full model) the 
fixed factor in question. Pairwise comparisons between 
timepoints were performed using the emmeans pack-
age [34] and the Benjamini–Hochberg procedure for 
the control of the false discovery rate (FDR). In the 
models with biomarkers (which were rank-trans-
formed), taxa and metabolic pathways, the mode of 
delivery and breastfeeding time were also included as 
additional covariates and thus controlled for. The LRT 
p-values for taxa and metabolic pathways were FDR-
adjusted as above.
The gut microbial diversity, composition and metabolic 
pathways were analyzed with respect to zonulin and cal-
protectin biomarkers using a repeated measures correla-
tion method [35]. The repeated-measures correlation (an 
equivalent to the linear mixed-effects model with random 
intercept) was used to assess the association between the 
levels of the biomarkers and the alpha diversity, PCoA 
scores, taxa and metabolic pathway abundance, account-
ing for repeated measures for each participant.
In addition, an association between the differences 
(changes) among all time points were associated using 
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linear mixed-effect models with random intercepts 
(newborn ID as a random factor). The extent of the bio-
marker change was defined as the dependent variable 
(DV). Then, the time period/interval—a categorical vari-
able with ten levels indicating all possible differences (e.g. 
P2–P3, P2–P4, etc.) between the five time points (P2, P3, 
P4, P5 and P6, PMU cohort) or four time points (P2, P3, 
P4, P5, HMS cohort) and either beta-diversity (Bray–
Curtis intersample composition distance) or univariate 
metrics of changes in microbiota composition or meta-
bolic pathway abundance (between corresponding time 
points) were defined as fixed effects. To investigate the 
connection between the change in the overall compo-
sitional profile and the change in the levels of biomark-
ers, we took the within-subject Bray–Curtis distances 
(computed at the genus level using rarefied abundances). 
Fine-grained analysis was performed using changes in 
the taxonomic composition (from genus to phylum level) 
and metabolic pathways which were computed using the 
center-log transformed Monte Carlo instances of the 
Dirichlet distribution. Two sets of likelihood ratio tests 
were performed (with mode of delivery and breastfeed-
ing time as covariates). In the first LRT, a significance of 
the Bray–Curtis distance or change in abundance was 
assessed under the assumption of no interaction between 
the fixed factors (the common slope model). The second 
LRT was used to determine whether the interaction was 
statistically significant. In case of a significant interaction 
effect, the emmeans package was used (emtrends func-
tion) to estimate the individual slopes over levels of the 
time period/interval. The p-values for the slopes (coeffi-
cients) were determined and adjusted for multiple testing 
to control for the FDR. No imputation was undertaken 
for missing data so as not to make unwarranted assump-
tions on the distribution of measured features. Instead 
these cases were consistently omitted under the settings 
used for the R functions employed in our analysis. Data 
was manipulated using Perl. A significance level of 5% 
was used for raw and FDR adjusted p-values.
Results
Stool levels of zonulin and calprotectin increase 
and decrease over time, respectively
Both stool zonulin and calprotectin concentrations 
changed significantly over time in the cohort (Fig. 1, LRT, 
df = 4, P = 2.6e−05, and df = 4, P = 10.0e−05, respec-
tively; adjusted for the mode of delivery and breastfeed-
ing duration).
Zonulin levels at P2 (7 days after birth) and P3 (1 month 
after birth) were significantly lower than those at the 
time points P4, P5, and P6. However, from P4 to P6 (6th 
and 24th months of life), no significant differences were 
observed (between any two time points, non-consecutive 
or consecutive). Thus, zonulin levels tended to increase 
for up to 6 months after birth (P4) and stabilize thereafter 
(Fig. 1a). In contrast to zonulin, calprotectin levels did not 
differ significantly between any consecutive time points 
(Fig. 1b). Moreover, up to and including P4, none of the dif-
ferences in calprotectin levels between any two time points 
(non-consecutive or consecutive) were significant. How-
ever, the calprotectin levels at P5 were significantly lower 
than those at P2, P3; additionally, the calprotectin levels at 
P6 were also significantly lower than those at P2, P3, and P4 
(Fig. 1b). Overall, these results suggest that between about 
6 and 12 months of age, the zonulin levels stabilize remain-
ing at a high level, while calprotectin concentration begins 
to decline. Importantly, the analysis of the HMS validation 
cohort (Additional file 1: Figure S3) confirmed the declin-
ing trend of calprotectin from P3 onwards; of note, a sig-
nificant difference was determined between the first and 
sixth months of life, which altogether strongly highlights 
the sixth month of life as an important time point concern-
ing changes of analyzed markers after childbirth. Interest-
ingly, despite the observed opposite trends in the context of 
stool zonulin and calprotectin levels, the two markers (its 
changes) did not appear to correlate with each other (LRT; 
common slope model: df = 1, P = 0.776, β = 0.03, SE = 0.09; 
interaction model: df = 9, P = 0.419, Fig. 1c).
Gut microbiota diversity, taxonomy and metabolic 
pathways during the first two years of life
Gut microbiota diversity
The alpha diversity was measured using the Shannon 
index (Fig.  2a); sample diversity differed significantly 
between time points (LRT, df = 5, P = 6.61e−09). Specifi-
cally, P2′s alpha diversity was significantly lower than in 
P4, P5 and P6, whereas P3′s alpha diversity was signifi-
cantly lower than in P5 and P6. We have validated those 
results by comparing diversity in stool samples with 
that in meconium in the two cohorts of children (PMU 
and HMS). In the PMU, the Shannon indexes in P2 
(Q < 0.0001), P3 (Q = 0.0001), P4 (Q = 0.004) were signifi-
cantly lower than that in P1; on the other hand, the Shan-
non indexes in P5 (Q = 0.109) and P6 (Q = 0.201) did not 
differ significantly from that. Altogether, these results 
indicate that the meconium samples have the highest 
alpha diversity; interestingly, our data suggest that the 
newborn’s gut microbiota diversity first decreases but 
then is restored over time (Fig. 2a). Importantly, a similar 
pattern was evident in the HMS cohort data (Additional 
file  1: Fig.  4a), except for a clear discrepancy between 
the first samples’ diversity (in the HMS cohort, the low-
est diversity was detected at day 1, giving rise to a mono-
tonically increasing trend in this cohort). This can occur 
if “high diversity” meconium samples (bacteria derived 
from the mother and environment following birth [36] 
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are combined with early newborns’ stool “low diversity” 
samples (in the PMU cohort, only meconium stool sam-
ples were analyzed while in the HMS cohort also the first 
stool samples were analyzed in some cases).
The ordination of samples in a two-dimensional space 
performed as per a principal coordinate (PCo) analy-
sis on Bray–Curtis distances dissimilarity based on 
genus abundance showed a sequential change in the 
gut microbial communities (Fig.  2b), especially along 
the PCo2 axis, where the transition of the gut microbial 
composition was smooth and gradual so that the differ-
ences in the PCo2 scores were significant only between 
more distant time points, i.e. P2–P4/P5/P6, P3–P5/P6 
and P4–P6 (Fig. 2d). The meconium community compo-
sition was markedly dissimilar from those in later sam-
ples in both cohorts. This was especially evident along 
the PCo1 axis (Fig.  2c, Additional file  1: Figure S4C): 
in the PMU, the PCo1 scores were significantly differ-
ent among all time points except for P4. While a global 
multivariate test for impact of time (partial Mantel test 
Fig. 1 Dynamics of stool zonulin and calprotectin levels. a zonulin, b calprotectin. Notched boxplots with variable widths proportional to the 
square‑roots of the number of observations in the groups are shown; FDR adjusted p‑values < 0.05 are represented. c correlation between the stool 
zonulin and calprotectin changes (rank‑transformed, adjusted for the mode of delivery and breastfeeding time); P2‑7th day, P3‑1st month, P4‑6th 
month, P5‑12th month, P6‑24th month; PX‑PY‑difference between the time points X and Y
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on Bray–Curtis dissimilarities relative to intersample 
time interval and donor incongruence matrices) does not 
achieve significance, we see significant (PCo1 scores by 
time, LRT, df = 5, P = 0.004; PCo2 scores by time, LRT, 
df = 5, P = 5.19e−08) differences between time points 
with regards to the first two principal coordinates of the 
gut taxonomic data, indicating an overall shift in sample 
composition over time nonetheless takes place (Fig.  2c, 
d). Altogether, these results align with previous findings 
regarding taxonomic composition of the meconium and 
fecal samples [25, 36], validating the microbial analysis 
methods used.
Fig. 2 Gut microbiome: alpha and beta diversity over time. a Shannon alpha diversity by time, LRT, df = 5, P = 5.25e−09, adjusted for breastfeeding 
time and mode of delivery; b Principal coordinate analysis plot with Bray–Curtis dissimilarity calculated from genus abundances, ellipses were 
drawn assuming a multivariate t‑distribution; c PCo1 scores by time, LRT, df = 5, P = 0.004; d PCo2 scores by time, LRT, df = 5, P = 5.19e−08; FDR 
adjusted p values < 0.05 are shown, P1‑meconium, P2‑7th day, P3‑1st month, P4‑6th month, P5‑12th month, P6‑24th month
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Gut microbiota composition and functional profiles 
during the first two years of life
The bacterial taxonomic and functional (PICRUSt2-
predicted) development during the first 2  years of 
life was analyzed using linear mixed-effect modeling 
of the centered log-ratio transformed 128 Monte 
Carlo instances of the Dirichlet distribution in sam-
ples from 7th day (P2) to the 24th month (P6) of age. 
Twenty-seven out of 47 evaluated genera that met the 
prevalence criterion either increased or decreased 
significantly during that period (Fig. 3a). Of note, the 
changes in the Staphylococcus and Ruminococcus (tor-
ques group) abundance were approximately mono-
tonic throughout that time (Fig.  3b). In general, the 
abundance tended to stabilize around 1  year of life 
(P5) with only mild alterations thereafter (see the col-
umn P5P6 in Fig. 3a). Interestingly, except for Staphy-
lococcus, the abundance was relatively constant until 
the end of the first month of life (P3, see the P2P3 col-
umn in Fig. 3a). Longitudinal changes in the bacterial 
composition at higher taxonomic ranks are shown in 
Additional file 1: Figure S5.
Remarkably, fifteen genera whose abundance 
changed significantly over time overlapped between 
the PMU and HMS cohorts (Fig. 3a, Additional file 1: 
Figure S6). This overlap accounted for 60.0% and 
51.7% of the significantly affected taxa in the PMU 
(P2 to P6) and HMS (P2 to P5), respectively. Moreo-
ver, for overlapping genera, the patterns of temporal 
changes in abundance were similar (either decreas-
ing or increasing); the degree of changes between 
time points also exhibited a similar pattern (i.e. P2P3, 
P2P4, P3P4).
To infer the functional profile of the microbial com-
munities, we used the PICRUSt2 software. We identi-
fied 110 MetaCyc pathways (out of 332 predicted) in 
the PMU cohort that were significantly associated with 
time. In general, almost all pathways (except PWY-
7332) did not change significantly in abundance after 
P5, and the majority of pathways stabilized even ear-
lier at around the 6th month of age (P4). In the HMS 
cohort, the analysis of predicted MetaCyc pathways 
revealed 223 pathways (out of 290 predicted) whose 
abundance changed significantly over the observation 
period (P2 to P5). Importantly, there were 76 pathways 
whose abundance changed over time in the two cohorts 
(Additional file  1: Figure S7), accounting for 75.2% 
and 34.1% of the significant pathways in the PMU and 
HMS cohorts, respectively. Remarkably, there was a 
very high degree of consistency between the cohorts 
regarding the direction and dynamics of the pathways’ 
abundance.
Gut microbiota diversity, composition and metabolic 
pathways concerning the stool levels of zonulin 
and calprotectin
Next, we focused on the relationships between micro-
biota diversity, composition, predicted function and 
permeability/inflammatory markers. In a first step, we 
assessed whether the time intervals with significant 
changes in bacterial diversity, abundance and predicted 
metabolic functions overlapped with the time intervals 
associated with an increase in zonulin (i.e. P2–P4/P5/P6, 
P3–P4/P5/P6) and decrease in calprotectin (i.e. P2–P5/
P6, P3–P5/P6, P4–P6). Then, in a second step, we used 
a statistical technique (repeated measures correlation) 
that accounts for non-independence among observa-
tions comprising the entire observation period (from P2 
to P6), to investigate the associations between the bacte-
rial diversity, abundance and predicted metabolic func-
tions and the concentration of zonulin or calprotectin. 
In a third step, mixed effects linear models were used to 
investigate the relationship between changes in bacterial 
diversity, abundance and metabolic function and the cor-
responding changes in the concentration of zonulin and 
calprotectin between all time point pairs.
The compatibility of observations obtained at all stages 
of the analysis was considered as potential evidence of 
a causal relationship between the microbiota and the 
markers analysed. To make this analysis easier accessible, 
these data are included in summary tables (Additional 
file 1: Table S5).
Diversity
The Shannon index increased significantly in five out of 
six time intervals associated with a significant increase 
in zonulin (i.e. P2–P4/P5/P6, P3–P5/P6, Figs.  1a, 2a) 
and in four out of five time intervals associated with a 
significant decline in calprotectin (P2–P5/P6, P3–P5/
P6, Figs. 1b, 2a). To investigate whether or not a relation-
ship exists between the alpha diversity and stool zonulin/
calprotectin levels, we performed correlation analysis 
between four alpha-diversity indices (Shannon, Simp-
son, Chao1, Evenness) and the levels of these biomarkers 
using repeated measures correlation. The zonulin levels 
did not correlate with any of the alpha diversity indices 
(after FDR adjustment). In contrast, the levels of calpro-
tectin inversely correlated with all of the alpha diver-
sity indices calculated (Shannon’s-r = − 0.30, Q = 0.039; 
Simpson’s-r = − 0.23, Q = 0.048, Chao1-r = − 0.24, 
Q = 0.048, Evenness-r = − 0.24, Q = 0.048); of note, the 
strongest correlation was found for the Shannon’s diver-
sity (Fig. 4a).
The PCo2 scores decreased significantly in five out 
of the six time intervals associated with a significant 
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rise in zonulin (P2–P4/P5/P6, P3–P5/P6, Figs.  1a, 2d) 
and in all five time intervals associated with a signifi-
cant decrease in calprotectin (P2–P5/P6, P3–P5/P6, 
P4–P6, Figs.  1b, 2d). Besides, there was some similar-
ity between the longitudinal zonulin and PCo1 scores 
pattern (Figs.  1a, 2c). Therefore, we explored the cor-
relations between the zonulin and calprotectin levels 
and the per-sample positions on the first two PCoA 
axes using repeated measures correlation analysis. We 
did not find any significant correlation (zonulin and 
PCo1: r = 0.06, P = 0.637; zonulin and PCo2: r = − 0.23, 
P = 0.053; calprotectin and PCo1: r = 0.11, P = 0.363; 
calprotectin and PCo2: r = 0.19, P = 0.109) suggest-
ing that the overall compositional profiles (captured 
by the first two PCo dimensions) were not associated 
with the levels of zonulin or calprotectin (Fig.  4b, c). 
Moreover, using likelihood ratio tests of the nested 
models, no association the between Bray–Curtis dis-
tances and the changes in the zonulin levels was found 
(non-interaction model: df = 1, P = 0.121, Q = 0.241; 
interaction model: df = 9, P = 0.965, Q = 0.965). How-
ever, there was a significant association between the 
Bray–Curtis distances and the changes in calprotectin 
levels (time period x calprotectin change interaction 
model: df = 9, P = 0.013, Q = 0.025). The post-hoc tests 
revealed significant correlations between the changes 
in calprotectin levels and the Bray–Curtis distances for 
P2–P3 and P3–P4; however, they were not significant 
after FDR adjustment (Q = 0.216 and Q = 0.110, respec-
tively, Fig. 4d).
Microbiota composition and functional profiles 
concerning stool zonulin and calprotectin
Despite the lack of associations between alpha diversity 
and the zonulin levels as well as between beta diversity 
and the levels of both biomarkers (zonulin and calpro-
tectin) (Fig.  4), we sought to examine more particular 
relationships between the levels of these permeability/
inflammation-associated biomarkers and the abundances 
of specific gut bacterial taxa in the context of five taxo-
nomic ranks (from genus to phylum levels) as well as the 
PICRUSt2-predicted MetaCyc metabolic pathways.
Interestingly, the changes in abundance of several 
bacteria coincided with significant time dependent 
changes in the levels of zonulin or calprotectin (Figs.  1, 
3a). For example, there was an increase in the abun-
dance of Lachnoclostridium, Ruminococcus (gnavus 
group), Carnobacteriaceae, Lachnospiraceae, Pepto-
streptococcaceae, Coriobacteriales, and a decrease of 
Corynebacteriales among all time points associated with 
an increase in the zonulin concentration. Additionally, 
there was an increase in the abundance of Anaerostipes 
Fig. 3 Changes in the gut microbiota composition during first two years of life. a linear mixed effects analysis followed by pairwise comparison of 
time‑ points (adjusted for mode of delivery and breastfeeding time), a Genera (present in at least 20% samples) significantly associated with time, 
b Longitudinal abundance of the Staphylococcus and Ruminococcus (torques group). The overall p‑value—a likelihood ratio test (LRT) of nested 
models (FDR adjusted across genera); PXPY—contrast p values between the two time points (PX and PY), FDR adjusted for all possible contrasts, 
t.ratio—t statistics for the contrasts estimates (a positive value, colored blue, indicates a decrease in abundance, a negative value, colored red, 
indicates an increase in abundance). Red arrows indicate time intervals with a significant increase of zonulin, blue arrows indicate time intervals 
with a significant decrease of calprotectin (see also Fig. 1). Taxa abundances (unrarefied) were transformed by generating 128 Monte Carlo instances 
of the Dirichlet distribution for each gut sample, followed by center‑log transform of each instance. A linear mixed effects analysis was performed 
for each instance separately and the results were averaged over 128 instances. P2-7th day, P3-1st month, P4‑6th month, P5‑12th month, P6‑24th 
month
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and a decrease in the abundance of Enterococcaceae 
among all time points associated with a decrease in cal-
protectin concentration. To investigate this further, we 
computed the repeated measures correlations (encom-
passing the whole study period; Fig.  5 and Additional 
file 1: Table S5) between the levels of both markers and 
the gut microorganisms.
In the correlations between gut microorganisms and 
stool calprotectin, we observed significant associations 
at the genus level (n = 3), the family level (n = 3), and the 
order level (n = 1). Moreover, the levels of zonulin were 
correlated with the abundance of 19 microorganisms: at 
the genus level (n = 5), at the family level (n = 5), at the 
order level (n = 5) and the class level (n = 4) (Fig. 5a and 
Additional file 1: Table S1). Specifically, calprotectin cor-
related positively with Staphylococcus, Enterococcus, 
Staphylococcacae, and Enterococcaceae and negatively 
with Anaerostipes, Ruminococcacea and Clostridi-
ales, whereas zonulin correlated positively with Lach-
noclostridium, the Ruminococcus (gnavus group), the 
Fig. 4 Alpha and beta diversity (Bray–Curtis distance) compared to zonulin and calprotectin. a Repeated measures correlation between 
calprotectin and Shannon diversity index. b Repeated measures correlation between zonulin and PCo1 scores, c Repeated measures correlation 
between calprotectin and PCo2 scores, d Correlation between Bray–Curtis distance and calprotectin change for all possible time point pairs. 
Significant likelihood ratio test (LRT) indicating an interaction between time period and calprotectin change (df = 9, P = 0.013, Q = 0.025), post‑hoc 
test revealed significant correlations between Bray–Curtis distance and calprotectin change between P2 and P3 (β = 2.18e−03, P = 0.043) and P3 
and P4 (β = − 2.31e−03, P = 0.011); alpha diversity, zonulin calprotectin and calprotectin change were rank transformed, repeated measures and 
correlation trend lines are coloured by individual child. PCo1 and PCo2 scores were treated here as a dimensionality‑reduced measure of sample 
composition relative to whole‑dataset variability
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Ruminococcus (torques group), Lachnospiraceae, Pepto-
streptococcaceae, Ruminococcacea, Erysipelotrichales, 
Coriobacteriales, Clostridiales, Clostridia, Coriobacteria 
and negatively with Staphylococcus, Corynebacterium, 
Moraxellaceae, Staphylococcaceae, Bacillales, Pseudomo-
nadales, Alphaproteobacteria, and Bacilli. Of note, the 
genus Staphylococcus, the families Ruminococcaceae 
and Staphylococcaceae, and the order Clostridiales were 
simultaneously and oppositely correlated with both bio-
markers in the PMU cohort (Fig. 5a) and with calprotec-
tin in the HMS cohort, exhibiting the same direction and 
similar magnitudes as those in the PMU cohort (Addi-
tional file  1: Table  S2). Additionally, zonulin correlated 
significantly with 10 MetCyc pathways belonging to 4 
superclasses (Superpathways: FUC-RHAMCAT-PWY, 
Degradation/Utilization/Assimilation: FUCCAT-PWY, 
PWY-6353, PWY-7237, SALVADEHYPOX-PWY, Gen-
eration of Precursor Metabolites and Energy: PWY-5676, 
PWY-5677, PWY-6588, PWY-7003, and Biosynthesis: 
PWY-6478), of which two pathways, PWY-5677 and 
PWY-6588, were the only pathways associated with cal-
protectin (Fig. 5b). The correlation between calprotectin 
and predicted metabolic pathways from the HMS cohort 
revealed 15 pathways significantly correlating with cal-
protectin levels; however, none of them overlapped with 
the correlations found in the PMU cohort (Additional 
file 1: Table S2).
In order to gain more insight into the causal rela-
tionship between the microbiota and zonulin/cal-
protectin, the changes in the gut community features 
(taxonomic composition and functional profile) and 
the changes in the levels of zonulin or calprotectin 
among the time points were correlated using a linear 
mixed-effects model. We did not find any association 
between changes in microbiota and changes in mark-
ers, except for the genus Ruminococcus (torques group) 
which was significantly associated with the changes in 
levels of calprotectin. he interaction model did not fit 
significantly better than the common (positive) slope 
model (Fig. 6a, Table 2). Thus, the abundance of Rumi-
nococcus (torques group) changes in parallel with the 
changes in stool calprotectin levels regardless of time 
interval (which is especially prominent for the P2–P4, 
P2–P5, P3–P4, P4–P6 time intervals), thereby suggest-
ing that both can be causatively connected. However, 
this observation was not confirmed in the validation 
analysis and must be taken with caution. The analysis 
in the context of higher taxonomic ranks for the PMU 
and HMS cohorts are shown in the Additional file  1: 
Figures S8–S10.
Fig. 5 Significant repeated measures correlations of zonulin and calprotectin with microorganisms and PICRUSt2 predicted MetaCyc pathways. 
a taxon correlation network, b MetaCyc pathway correlation network node size and edge width are proportional to microorganisms/pathways 
abundance and repeated measure correlation coefficients, respectively; line color indicates the negative (blue) and positive (red) correlations, node 
color indicates taxonomic rank or metabolic pathway categories. Taxonomic abundances (unrarefied) were transformed by generating 128 Monte 
Carlo instances of the Dirichlet distribution for each gut sample, followed by center‑log transform of each instance
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In addition to the changes in the composition of the 
human gut microbiota, we also investigated whether the 
changes in functional profiles of gut microbiota were 
linked to the dynamics of the zonulin or calprotectin lev-
els. Remarkable, we found that the dynamics of stool cal-
protectin was negatively associated with changes in two 
MetaCyc metabolic pathways: pyruvate fermentation to 
butanoate (CENTFERM-PWY) and the superpathway 
of Clostridium acetobutylicum acidogenic fermenta-
tion (PWY-6590) (Fig. 7c, d). The common slope model 
was the best fit for these pathways (Table  2). For zonu-
lin, the common slope model was the best fit for a change 
in the pentose phosphate pathway (PENTOSE-P-PWY) 
only Fig. 7a, Table 2). In addition, the dynamics of zonu-
lin was associated with changes in 3 MetaCyc pathways: 
pyrimidine deoxyribonucleotides de novo biosynthesis 
III (PWY-6545), the superpathway of glucose and xylose 
degradation (PWY-6901), and the super pathway of pyri-
doxal 5′-phosphate biosynthesis and salvage (PWY0-
845). For those 3 pathways, as illustrated in Fig.  7b for 
PWY-6545, the models with different slopes (i.e. includ-
ing an interaction between all time point pairs and path-
way changes) fitted the data significantly better than the 
common slope model. For example, the change in zonulin 
levels was associated negatively with a change in PWY-
6545 (Fig.  7b, Table  2) between P3 and P4 (P = 0.001, 
Q = 0.012), yet positively between P4 and P6 (P = 0.003, 
Q = 0.012) as well as P5 and P6 (P = 0.004, Q = 0.012). 
For the other two pathways, PWY-6901 and PWY0-845 
(Table  2), significant associations were found between 
P3 and P4 (β = 23.60, SE = 7.35, P = 0.002, Q = 0.008) 
as well as P5 and P6 (β = 36.08, SE = 10.56, P = 0.0008, 
Q = 0.008) for PWY-6901, and between P3 and P4 for the 
PWY0-845 (β = 13.07, SE = 3.66, P = 0.0005, Q = 0.005). 
For the full results, see Additional file 1: Tables S3 and S4.
However, it should be noted that the above results 
(concerning calprotectin) were not confirmed in the 
HMS cohort: 44 pathways showed a correlation with the 
dynamics of calprotectin (all under the common slope 
model), but the CENTFERM-PWY (P = 0.051, Q = 0.131) 
and PWY-6590 (P = 0.056, Q = 0.140) did not (Additional 
file 1: Figure S11). The relationships between the changes 
in abundance in the gut, the MetaCyc pathways, and the 
changes in calprotectin levels in the HMS cohort are 
shown in Additional file 1: Figure S12.
Discussion
This is the first study in which putative associations 
between the gut microbiota and the concentrations 
of zonulin and calprotectin in children’s stool dur-
ing the first 2  years of life have been investigated. 
The study of zonulin allows the non-invasive assess-
ment of the functional state of the small intestinal 
paracellular permeability; additionally, the calprotectin 
measurements provide insight into the development of 
the immune system after birth. The observed changes of 
both markers concentration indicate that the 6th month 
of life can be defined as the key point for forming the 
small intestinal barrier and for the development of post-
natal immunity. It should also be stressed that, usually, 
in the sixth month of life, solid food is introduced to 
children’s diet, which can significantly impact both gut 
microbiota and intestinal permeability.
Although zonulin seems to be a valuable marker of 
small intestinal paracellular permeability, the data in the 
context of children aged 2 years old or younger are scarce 
and focused on infections [37] and prematurity [38]. 
The fecal zonulin concentration in children during the 
first 2  years of life was not reported and its role during 
this period is unknown. Its relationship with gut micro-
biota seems to be interesting [38]. Zonulin is involved 
in controlling the passage of molecules weighing at least 
3.5 kDa [39] through the intestinal barrier via its reverse 
influence on TJ tightness [40, 41]. After the activation of 
ZO-1, zonulin controls the low-capacity “leak” type route 
characterized by low selectivity [42, 43]. Interactions 
between zonulin and gut microbiota can be bidirectional. 
Bacterial and gluten exposure was defined as intensive 
triggers of zonulin release [19, 44]. Of note, the zonulin 
pathway is an innate defensive mechanism of the host, 
able to control the gut microbiome composition via the 
“flushing out” of microorganisms by water secreted into 
the intestinal lumen following hydrostatic pressure gra-
dients [45]. High stool zonulin levels suggest that the gut 
barrier allows the free flow exchange of various particles 
in infants. Moreover, it is likely that the commercially 
available ELISAs detect one or more members of the 
zonulin family that have not been discovered yet but play 
some important role during the first 2 years of life [46].
High levels of calprotectin in feces during the first 
months of life are associated with the regulation of the 
development of the immune system in neonates as well 
as with the adaptation to new environmental conditions 
[25]. The decrease in the fecal calprotectin concentra-
tion implies that inflammatory processes in the gut tend 
to decrease from the 6th month of age, which, with the 
accompanying increased paracellular intestinal perme-
ability and bacterial alpha diversity, provides suggestion 
of immune tolerance. Willers et  al. [25] demonstrated 
that mice exposed to calprotectin immediately after 
birth induced microbial tolerance against the first wave 
of microbial colonization; on the other hand, the same 
exposure after the neonatal period was associated with 
pro-inflammatory responses. Wood et  al. observed an 
increased proportion of regulatory T cells (Tregs) dur-
ing the first three weeks of life [47] which is associated 
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Fig. 6 Relationship between gut genus abundance and calprotectin levels (changes per time interval). a Linear mixed effects models were used 
to test for an association between the taxon abundance change and calprotectin change accounting for ten time point pairs (P2–P3, P3–P4, etc.) 
from the same subject, adjusted for mode of delivery and breastfeeding time. Two models were considered: without interaction (w/o int.) and with 
interaction between time point pair and taxon change (w/ int.). If the interaction term was significant—Q (w/ int.) < 0.05, individual p values (FDR 
adjusted) were interpreted. If the common slope model was chosen—Q (w/o int.) < 0.05 and Q (w /int) > 0.05, the same common slope coefficient 
β (coef.) across all time points and one p‑value (P2–P3) were shown. Coefficients and Q values were averaged over 128 Monte Carlo instances of the 
Dirichlet distribution, followed by center‑log transform of each instance, b the common slope model (LRT, df = 1, P = 0.002, Q = 0.015) illustrating 
relationships between Ruminococcus (torques group) change (centered log‑ratio transformed) and calprotectin change (rank transformed)—based 
on the first Monte Carlo instance
Table 2 Association of the marker change (zonulin, calprotecin) with taxon/pathway change—a linear mixed model
β, coefficient estimate; SE, standard error; Q -FDR adjusted P value, Na, not applicable
Taxon/Pathway vs marker (changes) Common slope (no interaction) Interaction (taxon/
pathway change x time 
interval)
β (SE) P Q P Q
Ruminococcus (torques group) vs calprotectin 2.94 (0.81) 0.002 0.015 0.424 0.910
CENTFERM‑PWY vs calprotectin − 4.54 (1.08) 0.0002 0.028 0.412 0.993
PWY‑6590 vs calprotectin − 4.48 (1.16) 0.0002 0.026 0.421 0.993
PENTOSE‑P‑PWY vs zonulin 9.49 (1.93) 3.98e−6 0.001 0.123 0.356
PWY‑6545 vs zonulin Na – – 4.15e‑5 0.014
PWY‑6901vs zonulin Na – – 0.0005 0.046
PWY0‑845 vs zonulin Na – – 0.0008 0.049
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with increased immune tolerance after the birth. Our 
results did not fully corroborate these observations. The 
intestinal permeability in the first month of life, as per 
the zonulin concentration, is lower than that in the later 
period, suggesting that the possibility of antigen translo-
cation early after birth is limited. After the sixth month of 
age, the intestinal paracellular permeability increases, but 
this does not increase inflammation, as per the calpro-
tectin concentration, which indicates the development 
of immune tolerance. The differences between the two 
studies may be due to the fact that Willers et al. did not 
directly measure intestinal permeability and additionally 
Fig. 7 Relationship between (changes in) gut abundance of inferred MetaCyc pathways and (changes in) zonulin/calprotectin levels. a The 
common slope model (LRT, df = 1, P = 3.98e−6, Q = 0.001) illustrating relationships between PENTOSE‑P‑PWY change (centered log‑ratio 
transformed) and zonulin change (rank transformed), b the model with time point pair by PWY‑6545 change interaction (LRT, df = 9, P = 4.15e−5, 
Q = 0.014), c common slope model illustrating relationships between CENTFERM‑PWY change (centered log‑ratio transformed) and calprotectin 
change (rank transformed), d common slope model illustrating relationships between PWY‑6590 change (centered log‑ratio transformed) and 
calprotectin change (rank transformed); Likelihood ratio test (LRT) P‑ and Q‑values were computed based on 128 Monte Carlo instances of the 
Dirichlet distribution, followed by center‑log transform of each instance, the plots were based on the first Monte Carlo instance
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used an animal model that does not closely mimic the 
timing of human intestinal barrier development and 
Wood et  al. measured Treg proportion only during the 
first three weeks of life however. As such, direct compari-
son of immune tolerance as reported by them and as per 
our present study is not possible, and we look forward 
to future studies bridging this gap. Moreover the role of 
paracellular way in translocation of bacteria and endo-
toxin is still the subject of debate [22], what requires that 
the observed results should be interpreted with caution.
In summary, the increased production of zonulin 
may be caused by changes in intestinal bacteria and by 
the introduction of gliadin into the diet. In contrast, the 
decrease in the calprotectin content in the stool may 
indicate immunological tolerance development. How-
ever, the breast milk is an essential source of calprotectin, 
which can significantly influence the fecal calprotec-
tin content. This said the observed changes cannot be 
explained solely by environmental factors as zonulin 
decreases in the later years of life despite the constant 
consumption of gliadin. Therefore, in the context of lon-
gitudinal analyses of biomarker trajectories, we applied 
corrections for the time of breastfeeding and the type of 
delivery to minimize the influence of these confounders. 
To help resolve the mechanisms underlying our results, 
we decided to analyze whether a cause-effect relation-
ship between the microbiota and the biomarkers would 
be observed. Of note, the microbial changes in the first 
2 years of life are very dynamic and depend on the age, 
mode of delivery, feeding, antibiotic treatment, and other 
environmental factors [28, 29]. However, a comprehen-
sive analysis of all factors influencing the gut microbiota 
is beyond the scope of this study, which is focused on 
the relationship between the microbiota and the fecal 
zonulin and calprotectin content. This said the composi-
tional and functional comparison of the PMU and HMS 
cohorts’ microbiota would be very interesting.
The Shannon index (more sensitive to species rich-
ness), shared 5 and 4 significant time intervals with 
zonulin (increasing) and calprotectin (decreasing), 
respectively. Similar results were observed for coordi-
nates of the first two axes in the context of a principal 
coordinate analysis based on the Bray–Curtis distance, 
one of beta-diversity measures. However, it translated 
only into a negative correlation between alpha-diversity 
indices, the Shannon index in particular, and calprotec-
tin. This negative correlation may be associated with the 
development of immunological tolerance. The microbial 
colonization of the intestine after birth will generate a 
diversity of new antigens that will play an important role 
in the stimulating of epithelial function and the establish-
ing the offspring’s immune system [48]. Of note, weaning 
(the average breastfeeding time in our study was about 
30 weeks), and the resulting loss of milk-borne calprotec-
tin, sIgA and other anti-microbial factors, along with the 
transition from mothers’ milk to a complex diet (includ-
ing solid food), can have a major impact on the dynamic 
microbiota development, and thus in the resulting 
immune responses during the neonatal period [6].
Willers et  al. [25] reported that the gut microbiota’s 
overall diversity significantly increases during the first 
year of life, similarly to what we observed in this study. 
Moreover, they observed the increased abundance of 
the bacterial classes Actinobacteria, Bacteroidia [49–51] 
and Clostridia, along with the decreased abundance of 
Bacilli and Gammaproteobacteria over the same time 
period. Of note, Willers et al. [25] demonstrated that dur-
ing infancy, high abundance of Actinobacteria and low 
abundance of Gammaproteobacteria are linked to high 
fecal calprotectin levels; additionally, at the family level, 
fecal calprotectin promoted the higher abundance of Bifi-
dobacteriaceae and the reduction of Enterobacteriaceae 
via the production of acetate [52]. Taxonomic composi-
tion observed by Willers et al. [25] might be linked to the 
elevation in the synthesis and reduction in the degrada-
tion of SCFAs and therefore leading to the overrepre-
sentation of health-promoting gut microbiota metabolic 
functions. Our results confirm the observations obtained 
by Willers et al. [25] in terms of abundance; however, the 
correlations in the cited study were not reproduced here. 
Importantly, the observed differences may depend on the 
difference between the investigated populations (Polish 
and German) or/and the analytical methods used. This 
said the analysis of both data-sets showed similarities 
with respect to the correlation between the levels of cal-
protectin and bacteria at the family level.
Interestingly, the bacteria associated with zonulin and 
calprotectin (Table  3) may be involved in the produc-
tion of SCFAs, which is a protective factor in the context 
of intestinal barrier integrity and of inflammatory pro-
cesses. Particularly, the different taxonomic groups of 
bacteria within the class Clostridia were associated with 
increased zonulin and decreased calprotectin concen-
trations. Within this class, the family Ruminococcaceae 
was more abundant in women with low zonulin concen-
trations in a previous study; however, here, we observed 
the opposite pattern. Importantly, not all bacteria within 
this class have the same properties. For instance, the 
genus Ruminococcus (gnavus group)—positively cor-
related with fecal zonulin concentration, is increased 
in patients with IBS-D and Crohn’s disease, which sug-
gests its pro-inflammatory activity. An interesting result 
was obtained in the case of the Ruminococcus (torques 
group). Ruminococcus torques, a butyrate producer, have 
been found to dominate patients’ gut milieu with Crohn’s 
Disease [53, 54]. They were also studied in the context 
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of individuals with increased risk of upper gastrointes-
tinal tract involvement, but with inconclusive results 
[55–57]. Importantly, Ruminococcus torques are able to 
utilize mucin in the human intestine, sustaining their 
adaptability to the human intestinal environment [54, 58, 
59]. Consequently, increased mucin degradation makes 
luminal antigens cross the gut barrier and stimulate the 
immune system, leading to intestinal disorders [60]. Of 
note, in this study, the abundance of these above bacte-
ria positively correlated with the concentration zonulin 
and the dynamics of calprotectin concentration. There-
fore, bacteria from the Ruminococcus (torques group) 
may include species associated with small intestinal per-
meability and immune responses in the first 2  years of 
life. For deeper species resolution and assessment of the 
gut functional potential future shotgun metagenomics, 
metabolomics.
It is not possible to draw definitive conclusions regard-
ing cause-effect relationships in a descriptive study like 
this, especially not given limited power due to sample size 
(see Methods). Moreover, we cannot exclude observed 
relationships could reflect hidden shared relationships 
with other covarying factors. However, as the associa-
tion between calprotectin and Ruminococcus abundance 
remained statistically significantly also accounting for 
age and delivery mode under stringent FDR adjustment, 
we can likewise conclude it is not reducible to the role 
of these factors, but rather constitutes an integral part 
of the system, with findings and implications beyond the 
age/maturity aspect. Details of the associations between 
bacteria and markers and bacteria properties are pre-
sented in Table  3. Only some of the relationships are 
discussed below. In this study, the Bacilli class correlated 
with decreased zonulin and increased calprotectin lev-
els. In general, this class is considered beneficial for gut 
health, which is in line with decreased zonulin levels. On 
the other hand, the family Staphylococcaceae and genus 
Staphylococcus from the Bacilli class are the most promi-
nent bacteria in human milk, an important calprotectin 
source in the infant. Family Enterococcaceae belongs to 
opportunistic pathogens, considered as potential marker 
for IBD, what can explain correlation with increased fecal 
calprotectin concentration. However, our present results 
do not allow consistent conclusions on the role of bac-
teria in the small intestinal barrier’s permeability or the 
immune system in the first 2  years of life. For example, 
the Lachnoclostridium genus produces SCFAs and occurs 
in lower amounts in patients with gastrointestinal can-
cers; therefore, in theory, it should decrease intestinal 
permeability; however, it was correlated with increased 
concentrations of zonulin in the neonatal stool in this 
study. Alphaproteobacteria occur in high numbers in 
patients with IBD and are negatively associated with the 
concentration of zonulin. The order Corynebacteriales 
is associated with decreased zonulin and belongs to the 
class Actinobacteria, which was positively correlated with 
calprotectin in the study by Willers et al. [25]. The order 
Pseudomonadales and the family Moraxellaceae are neg-
atively correlated with zonulin and belong to Gammapro-
teobacteria, negatively correlated with calprotectin in the 
study by Willers et al. Therefore, in no case was there a 
full consistency of microbiota changes between particular 
time points and changes in the levels of zonulin and/or 
calprotectin. This said the validation analysis suggested 
that the genus Staphylococcus and the family Staphylo-
coccaceae (positively correlated with the concentration 
of calprotectin), as well as the family Ruminococcaceae 
and the order Clostridiales (negatively correlated with 
the concentration of calprotectin), are potential candi-
dates as markers of the development of the immune sys-
tem in children under 2 years of age.
Finally, we analyzed the metabolic pathways linked 
with bacterial abundance (Table 4). We were able to show 
that the pathways involved in the production of SCFAs 
and the metabolism of carbohydrates were positively 
associated with fecal zonulin and negatively with calpro-
tectin. The latter association suggests the role of SCFAs 
in the immune response. Indeed, SCFAs regulate the 
body’s immune response through free fatty acid receptors 
(FFARs) that are expressed throughout the body, includ-
ing along the gastrointestinal tract [61]. SCFAs inhibit 
the activity of histone deacetylase (HADC), which acti-
vates gene expression in a pro-inflammatory response. 
Butyric acid plays a special role here via the binding of 
two butyrate molecules in the hydrophobic part of the 
enzyme, which is an example of the intracellular action of 
SCFAs. Moreover, the secretory activity of macrophages 
for the production of pro-inflammatory cytokines Il-6 
and IL-12 is reduced along with the increase of butyrate 
content. Some studies suggest that SCFAs initiate the 
transformation of naive  TCD4+ cells into regulatory cells, 
while others indicate SCFAs stimulate Treg cells already 
present in the colon [62–66]. Atarashi et al. [67, 68] dem-
onstrated that colonization of germ free rodents with 
appropriate strains of Clostridium influenced the multi-
plication and differentiation of Treg cells and stimulated 
anti-inflammatory cytokines synthesis, predominantly 
interleukin 10 (IL-10). Notably, butyric acid of all SCFAs 
is metabolized to the greatest extent by the colon epi-
thelial cells. Thus, it is the main source of energy for 
the colonocytes as it is responsible for maintaining the 
integrity of the intestinal barrier. This is evidenced by the 
effects of butyric acid supplementation of Caco 2 cells. 
Butyrate increased the concentration of ZO-1 and acti-
vated AMPK (adenosine monophospate activated protein 
kinase), which resulted in TEER (transepithelial electrical 
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resistance) increase. It is also known that butyric acid 
regulates cell proliferation and apoptosis, protecting 
against colorectal cancer [69, 70]. However, the positive 
associations and correlations between pathways involved 
in SCFAs production and the zonulin elevation are diffi-
cult to explain, suggesting that other mechanisms are also 
involved in regulating small intestinal barrier permeabil-
ity in children of up to 2 years old. It should be empha-
sized that the variations in the concentrations of zonulin 
and calprotectin overlapped with the introduction of new 
foods to the child’s diet around the sixth month of life 
(addition of soup, grated apple), with the consequent 
alteration in the gut microbiota composition and the 
related metabolic functions. For example, metabolic 
pathways involved in the metabolism of carbohydrates, 
vitamin B6 and nucleotides positively correlated with 
the levels of zonulin, which could suggest that an “open” 
small intestinal paracellular permeability could play a 
role in the transportation of metabolic reaction prod-
ucts during intensive growth and development. However, 
Table 4 Levels of associations between MetaCyc pathways and markers
a co-occurrence between change in the pathway abundance and change in zonulin (P2-P4/P5/P6, P3-P4/P5/P6) or calprotectin (P2-P5/P6, P3-P5/P6, P4-P6) levels: 
same—a change in the pathway abundance and change in marker level between time points occur in the same direction, opposite—a change in the pathway 
abundance and change in marker level between time points occur in the opposite direction. RMC (repeated measures correlation)—correlation between the pathway 
abundance and concentration of zonulin/calprotectin for paired measures assessed on six occasions (from P1 to P6, i.e., the entire observation period); LME (linear 
mixed-effects analysis)—an association between the pathway abundance change and marker change accounting for multiple time point pairs from the same subject, 
including time-point pair-specific relationships with either absence (the common slope model) or presence of the interaction (the different slopes model) between 
the abundance change and the time point pair); (+), positive RMC coefficient; (−), negative RMC coefficient
Metabolic pathway Changea RMC LME Pathway
ZON CALP
P‑163 PWY Same L‑lysine fermentation to acetate and butanoate
CENTFERM‑PWY Same Calp (common slope model, negative β coeff.) Pyruvate fermentation to butanoate
FUCCAT‑PWY Same Zon ( +) Fucose degradation
GLCMANNANAUT‑PWY Same Superpathway of N‑acetylglucosamine, 
N‑acetylmannosamine and N‑acetylneurami‑
nate degradation
PWY‑4984 Same Urea cycle
PWY‑6588 Same Zon (+),
Calp (−)
Pyruvate fermentation to acetone
PWY‑6590 Same Calp (common slope model, negative β coeff.) Superpathway of Clostridium acetobutylicum 
acidogenic fermentation
PWY‑6608 Same Guanosine nucleotides degradation III
PWY‑7003 Same Zon (+) Glycerol degradation to butanol
PWY‑7013 Same (S)‑propane‑1,2‑diol degradation
PWY‑7184 Opposite Pyrimidine deoxyribonucleotides de novo 
biosynthesis I
PWY‑7237 Same Zon (+) myo‑, chiro‑ and scyllo‑inositol degradation
FUC‑RHAMCAT‑PWY Zon (+) Superpathway of fucose and rhamnose 
degradation
PWY‑5676 Zon (+) Acetyl‑CoA fermentation to butanoate II
PWY‑5677 Zon (+),
Calp (−)
Succinate fermentation to butanoate
PWY‑6353 Zon (+) Purine nucleotides degradation II (aerobic)
PWY‑6478 Zon (+) GDP‑D‑glycero‑alpha‑D‑manno‑heptose 
biosynthesis
PENTOSE‑P‑PWY Calp (common slope model, positive β coeff.) Pentose phosphate pathway
PWY‑6545 Zon (different slopes model) negative β coeff.: 
P3‑P4;
positive β coeff.: P4–P6, P5–P6
Pyrimidine deoxyribonucleotides de novo 
biosynthesis III
PWY0‑845 Zon (different slopes model) positive β coeff.: 
P3–P4
Superpathway of pyridoxal 5′‑phosphate 
biosynthesis and salvage
PWY‑6901 Zon (different slopes model) positive β coeff.: 
P3–P4, P5–P6
Superpathway of glucose and xylose degrada‑
tion
SALVADEHYPOX‑PWY Zon (+) Adenosine nucleotides degradation II
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the paracellular transport of nutrients is known to play a 
rather minor role. The observed results support the con-
cept that paracellular permeability is only the component 
of intestinal barrier [22] and that SCFAs affect mostly 
transcellular route via metabolism of enterocytes. Of 
note, the analysis of the validation data did not confirm 
our observations concerning the metabolic pathways. 
Therefore, shotgun sequencing and metabolomic analy-
ses should be performed to shed more light on these pro-
cesses. All associations between metabolic pathways and 
markers were shown in Table 4.
Our study is not without limitations. Our cohort was 
relatively small, though enough to observe changes in 
zonulin and calprotectin levels as well as in gut micro-
biota composition during the first 2  years of life with 
appropriate power. The relatively small size of our data-
set (see power calculation section) does mean it is likely 
we may underestimate the relationship between per-
meability markers and the microbiota resulting in false 
negative findings, though we anticipate no increased risk 
of false positive such. However, the dataset size was at 
least sufficient to observe changes in zonulin and calpro-
tectin levels as well as in gut microbiota compositions, 
even at this reduced power. Moreover, our results were 
validated using the HMS cohort as well as via the com-
parison between the microbiota of meconium and stool 
samples collected at other time points. We therefore con-
sider our findings reliable although likely still incomplete. 
Moreover, our samples were somewhat heterogeneous 
(with respect to the delivery mode, the use of antibiot-
ics, nutrition, and other environmental factors). Of note, 
all of these factors and age development can affect the 
gut microbiota; however, in term infants, the mode of 
delivery seems to impact fecal calprotectin levels only in 
the first week of life [25]. Moreover, in our study, we did 
not use direct methods to measure the gut permeabil-
ity; we used biomarkers, for which data in healthy chil-
dren < 2  years old are limited. In fact, there are studies 
reported on the fecal levels of zonulin in adults but not in 
children. It is known that in children, the levels of zonu-
lin and calprotectin are incomparably higher than those 
in adults, changing over time, and could be influenced 
by e.g., breastfeeding, the dietary patterns, the mode of 
delivery, and the consumption of gliadin. In the current 
study, however, due to the small sample size, we did not 
analyze these biomarkers separately in the context of dif-
ferent delivery modes. Also, we did not collect detailed 
data on antibiotic exposure. Further, we did not measure 
these factors in blood (ethical reason—healthy children); 
only in stool. Moreover, since no metabolomic, lipid-
omic, immunological, or shotgun metagenomic analyses 
were performed, the results we obtained must be treated 
with caution. Mechanistic studies are still needed to 
investigate the relationship between microbiota and gut 
permeability and the immune system.
Conclusions
Overall, based on the results, we can conclude that the 
gut microbiota composition, the small intestinal para-
cellular permeability, as well as immune system-related 
markers change dynamically during the first 2  years of 
life. Although the gut microbiota composition and the 
related metabolic functions were correlated with zonulin 
and calprotectin levels, neither clear causation nor obvi-
ous health consequences can be proven in this study. 
However, our data may suggest that the Ruminococ-
cus (torques group) might be more involved in control-
ling paracellular permeability during the first 2  years of 
life than previously considered. Additionally, our data 
indicate that the genus Staphylococcus and the family 
Staphylococcaceae (positively correlated with the fecal 
calprotectin concentration) and the family Ruminococ-
caceae, as well as the order Clostridiales (negatively cor-
related with the fecal calprotectin concentration), may be 
potential biomarkers of the development of the immune 
system development or inflammatory reactions in chil-
dren younger than 2  years old. It must be emphasized 
that further longitudinal studies are required to inves-
tigate the mechanism behind gut permeability in chil-
dren and its influence on health. The establishment of 
gut permeability markers optimal for children as well as 
germ-free animal models, together with immunological, 
metabolomic and lipidomic studies (including the analy-
sis of SCFAs), are essential. This study’s translational sig-
nificance may follow from our observation may be that 
due to the of persistence of increased intercellular perme-
ability, at least until the age of two. If these observations 
can be robustly replicated, it may indicate health benefits 
of restricting exposure of very young children the child’s 
exposure to potential antigens, both food and environ-
mental, should be limited, balanced against the relative 
benefit of such exposure under the “hygiene hypothesis” 
of autoimmune aetiology, at least in particular subsets of 
vulnerable children. Bacterial and metabolic pathways 
associated with permeability markers may provide a basis 
for the search for pro- and postbiotics, and possibly serv-
ing as markers of intestinal permeability and gut immu-
nological status in young children that may help stratify 
recommendations.
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Additional file 1: Figure S1. Sample selection and availability (PMU 
cohort). From 100 healthy, full‑term newborns during the period from 
March 2015 to April 2016, 18 mother + child pairs were initially selected 
with the highest number of samples available. Since only in two cases the 
delivery was natural and neither the mother nor the child was treated 
with antibiotics, it was decided to supplement this cohort with six pairs of 
mother + child who were not given antibiotics and the delivery was 
natural. Out of the 24 newborns that were selected in this way, three 
newborns (F19, F22, F24) were excluded due to inadequate number of 
samples. Twenty‑one newborns (101 samples in total, green tiles) were 
included, in whom at least four longitudinal stool samples were available. 
Figure S2. Study flow chart, including zonulin and calprotectin (PMU 
cohort). The number of samples for downstream analyses might differ due 
to results out of determination limits (zonulin 800 ng/mL and calprotectin 
2100 ug/mL), technical problems (small volume of collected stool 
specimen, inadequate amount of DNA, sequencing depth), participant 
attrition. Figure S3. Stool calprotectin level by time in the HMS cohort. 
Likelihood ratio test, df = 3, P = 2.56e−10, adjusted for mode of delivery 
Notched boxplot with variable widths proportional to the square‑roots of 
the number of observations in the groups; FDR adjusted p‑values < 0.05 
are shown, P2—10th day, P3—1st month, P4—6th month, P5—12th 
month. Figure S4. Alpha and beta diversity over time in the HMS cohort. 
A—Shannon alpha diversity by time, LRT, df = 4, P < 2.2e−16, adjusted for 
mode of delivery, notched boxplot with variable widths proportional to 
the square‑roots of the number of observations in the groups, B—Princi‑
pal coordinate analysis plot with Bray–Curtis dissimilarity calculated from 
genus abundances, ellipses were drawn assuming a multivariate 
t‑distribution, C—PCo1 scores by time, LRT, df = 4, P = 2.97e−14, adjusted 
for mode of delivery; D—PCo2 scores by time, LRT, df = 4, P = 7.31e−11; 
FDR adjusted p values < 0.05 are shown P1—1st day (meconium/the first 
stool), P2—10th day, P3—1st month, P4—6th month, P5—12th month. 
Figure S5. Gut microbiota composition change over time (PMU cohort). A 
linear mixed effects analysis followed by pairwise comparison of time 
points (adjusted for mode of delivery and breastfeeding time). The overall 
p‑value—a likelihood ratio test (LRT) of nested models (FDR adjusted 
across genera); PXPY—contrast p values between the two time points (PX 
and PY), FDR adjusted for all possible contrasts, t.ratio—t statistics for the 
contrasts estimates (a positive value, colored blue, indicates a decrease 
abundance, a negative value, colored red, indicates increase in abun‑
dance). Taxa abundances (unrarefied) were transformed by generating 
128 Monte Carlo instances of the Dirichlet distribution for each gut 
sample, followed by center‑logtransform of each instance. A linear mixed 
effects analysis was performed for each instance separately and the results 
were averaged over 128 instances. P2—7th day, P3—1st month, P4—6th 
month, P5—12th month, P6—24th month. Figure S6. Gut microbiota 
composition change over time (HMS cohort). A linear mixed effects 
analysis followed by pairwise comparison of time points (adjusted for 
mode of delivery) for five taxonomic ranks (present in at least 10% 
samples), only taxons significantly associated with time are shown. The 
overall p‑value—a likelihood ratio test (LRT) of nested models (FDR 
adjusted across taxons); PXPY—contrast p‑values between the two time 
points (PX and PY), FDR adjusted for all possible contrasts, t.ratio—t 
statistics for the contrasts estimates (a positive value, colored blue, 
indicates a decrease in abundance, a negative value, colored red, indicates 
an increase in abundance). Taxa abundances (unrarefied) were trans‑
formed by generating 128 Monte Carlo instances of the Dirichlet 
distribution for each gut sample, followed by center‑log transform of each 
instance. A linear mixed effects analysis was performed for each instance 
separately and the results were averaged over 128 instances. P2—10th 
day, P3—1st month, P4—6th month, P5—12th month. Figure S7. 
Predicted MetaCyc pathways that change significantly over time in both 
cohorts (PMU and HMS). Linear mixed effects analysis followed by 
pairwise comparison of time points (adjusted for mode of delivery and 
breastfeeding time (PMU) and mode of delivery only in the HMS cohort). 
The overall p‑value—a likelihood ratio test (LRT) of nested models (FDR 
adjusted across pathways); PXPY—contrast p values between the two 
time points (X and Y), FDR adjusted for all possible contrasts, t.ratio—t 
statistics for the contrasts estimates. Pathway abundances (unrarefied) 
were transformed by generating 128 Monte Carlo instances of the 
Dirichlet distribution for each gut sample, followed by center‑log 
transform of each instance. A linear mixed effects analysis was performed 
for each instance separately and the results were averaged over 128 
instances. P2—7th day (PMU) or 10th day (HMS), P3—1st month, P4—6th 
month, P5—12th month, P6—24th month (PMU only). Figure S8. Taxon 
change versus zonulin change (PMU cohort). Linear mixed effects models 
were used to test for an association between the taxon abundance 
change and zonulin change accounting for ten time point pairs (P2‑P3, 
P3‑P4, etc.) from the same subject, adjusted for mode of delivery and 
breastfeeding time. Two models were considered: without interaction 
(w/o int.) and with interaction between time point pair and taxon change 
(w/ int.). If the interaction term was significant—Q (w/ int.) < 0.05, 
individual p values (FDR adjusted) were interpreted. If the common slope 
model was chosen—Q (w/o int.) < 0.05 and Q (w /int) > 0.05, the same 
common slope coefficient β (coef.) across all time points and one p‑value 
(P2–P3) were shown. Coefficients and Q values were averaged over 128 
Monte Carlo instances of the Dirichlet distribution, followed by center‑log 
transform of each instance. Figure S9. Taxon change versus calprotectin 
change (PMU cohort). Linear mixed effects models were used to test for 
an association between the taxon abundance change and calprotectin 
change accounting for ten time point pairs (P2‑P3, P3‑P4, etc.) from the 
same subject, adjusted for mode of delivery and breastfeeding time. Two 
models were considered: without interaction (w/o int.) and with 
interaction between time point pair and taxon change (w/ int.). If the 
interaction term was significant—Q (w/ int.) < 0.05, individual p values 
(FDR adjusted) were interpreted. If the common slope model was 
chosen—Q (w/o int.) < 0.05 and Q (w /int) > 0.05, the same common slope 
coefficient β (coef.) across all time points and one p‑value (P2‑P3) were 
shown. Coefficients and Q values were averaged over 128 Monte Carlo 
instances of the Dirichlet distribution, followed by center‑log transform of 
each instance. Figure S10. Taxon change versus calprotectin change 
(HMS cohort). Linear mixed effects models were used to test for an 
association between the taxon abundance change and calprotectin 
change accounting for six time point pairs (P2–P3, P3–P4, etc.) from the 
same subject, adjusted for mode of delivery. Two models were 
considered: without interaction (w/o int.) and with interaction between 
time point pair and taxon change (w/ int.). If the interaction term was 
significant—Q (w/ int.) < 0.05, individual p values (FDR adjusted) were 
interpreted. If the common slope model was chosen—Q (w/o int.) < 0.05 
and Q (w /int) > 0.05, the same common slope coefficient β (coef.) across 
all time points and one p‑value (P2‑P3) were shown. Coefficients and Q 
values were averaged over 128 Monte Carlo instances of the Dirichlet 
distribution, followed by center‑log transform of each instance. Figure 
S11. Pathway change vs calprotectin change (HMS cohort). Linear mixed 
effects models were used to test for an association between the pathway 
abundance change and calprotectin change accounting for six time point 
pairs (P2–P3, P3–P4, etc.) from the same subject, adjusted for mode of 
delivery. Two models were considered: without interaction (w/o int.) and 
with interaction between time point pair and taxon change (w/ int.). If the 
interaction term was significant—Q (w/int.) < 0.05, individual p values 
(FDR adjusted) were interpreted. If the common slope model was 
chosen—Q (w/o int.) < 0.05 and Q (w /int) > 0.05, the same common slope 
coefficient β (coef.) across all time points and one p‑value (P2‑P3) were 
shown. Coefficients and Q values were averaged over 128 Monte Carlo 
instances of the Dirichlet distribution, followed by center‑log transform of 
each instance. Figure S12. Relationship between (changes in) gut 
abundance of inferred MetaCyc pathways and (changes in) calprotectin 
levels (HMS cohort).A—common slope model illustrating relationships 
between CENTFERM‑PWY change (centered log‑ratio transformed) and 
calprotectin change (rank transformed), B—common slope model 
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illustrating relationships between PWY‑6590 change (centered log‑ratio 
transformed) and calprotectin change (rank transformed); Likelihood ratio 
test (LRT) p‑ and Q‑values were computed based on 128 Monte Carlo 
instances of the Dirichlet distribution, followed by center‑log transform of 
each instance, the plots were based on the first Monte Carlo instance. 
Table S1. Repeated measures correlation of zonulin and calprotectin with 
microorganisms and predicted MetaCyc pathways (PMU cohort). 
Table S2. Repeated measures correlation of calprotectin with bacteria and 
MetaCyc pathway abundance in the PMU and HMS cohorts. Table S3. 
Pathway change vs Zonulin change (PMU cohort). Table S4. Pathway 
change vs Calprotectin change (PMU cohort).
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